X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Researchers At Stanford Create A Novel Cancer Treatment

Content Team by Content Team
11th October 2022
in News, Research & Development

The molecule tigilanol tiglate, also known as EBC-46, could provide tailored treatment for diseases including cancer, as according research from Stanford University in the US that was recently published in the scientific journal Nature Chemistry.

The chemical is only naturally occurring in a tiny area of the northeastern Australian rainforest, in the fruit seeds of the blushwood tree (Fontainea picrosperma). Despite the compound’s complexity and difficulty in laboratory replication, Stanford researchers were able to create tigilanol tiglate.

Protein kinase C (PKC), which controls expression of genes and cell growth, is present in EBC-46. Small injections of EBC-46 into solid tumours changed the cellular signalling and activated specific PKC isoforms. This process affects the protein activity of malignant cells, resulting in the inflammation of tumours and the bleeding and degeneration of blood vessels.

The biotech company QBiotics in Australia first recognised tigilanol tiglate as having promise for application in medication development. The Stanford University team put this information to use and combined it for practical purposes.

The researchers utilised lab tools at the Stanford Cancer Institute Proteomics/Mass Spectrometry Shared Resource, the Stanford Sherlock cluster for computer modelling, and the Stanford Neuroscience Microscopy Service.

Researchers employed a Chinese herbal remedy called Croton tiglium (purging croton), which contains the active pharmaceutical ingredient (API) phorbol, to create the medication. The B ring of phorbol, which was chosen for alteration, received extra oxygen atoms.

His colleagues were able to accomplish what many people had assumed was impossible, said professor of chemistry at Stanford, Paul Wender, who also, graciously, teaches courses in chemical and systems biology.

They are learning more about how we can govern that functionality as we understand more about how cells function, he continued. This is crucial for dealing with rogue cells that cause diseases like cancer and Alzheimer’s.

Stelfonta, a therapy for mast cell cancer based on tigilanol tiglate, was approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2020. (the most common skin tumours in dogs). Since then, the substance has been the subject of human skin, head and neck, and soft tissue cancer clinical trials.

Previous Post

RNA Vaccine UK Innovation Centre At CPI Gets Fresh Funding

Next Post

Pistoia Alliance To Study Clinical Trial Ecology Effect

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

Pistoia Alliance To Study Clinical Trial Ecology Effect

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In